Cargando…
Botulinum toxin therapy of dystonia
Botulinum toxin (BT) is used to treat a large number of muscle hyperactivity syndromes. Its use in dystonia, however, is still one of the most important indications for BT therapy. When BT is injected into dystonic muscles, it produces a peripheral paresis which is localised, well controllable and f...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099791/ https://www.ncbi.nlm.nih.gov/pubmed/33125571 http://dx.doi.org/10.1007/s00702-020-02266-z |
_version_ | 1783688647095091200 |
---|---|
author | Dressler, Dirk Adib Saberi, Fereshte Rosales, Raymond L. |
author_facet | Dressler, Dirk Adib Saberi, Fereshte Rosales, Raymond L. |
author_sort | Dressler, Dirk |
collection | PubMed |
description | Botulinum toxin (BT) is used to treat a large number of muscle hyperactivity syndromes. Its use in dystonia, however, is still one of the most important indications for BT therapy. When BT is injected into dystonic muscles, it produces a peripheral paresis which is localised, well controllable and follows a distinct and predictable time course of around 3 months. Adverse effects are always transient and usually mild, long-term application is safe. With this profile BT can be used to treat cranial dystonia, cervical dystonia and limb dystonia including writer’s and musician's cramps. The recent introduction of BT high dose therapy also allows to treat more wide-spread dystonia including segmental and generalised dystonia. BT can easily be combined with other anti-dystonic treatments such as deep brain stimulation and intrathecal baclofen application. Best treatment results are obtained when BT therapy is integrated in the multimodal and long-term 'multilayer concept of treatment of dystonia'. The biggest challenge for the future will be to deliver state of the art BT therapy to all dystonia patients in need, regardless of whether they live in developed countries or beyond. |
format | Online Article Text |
id | pubmed-8099791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-80997912021-05-11 Botulinum toxin therapy of dystonia Dressler, Dirk Adib Saberi, Fereshte Rosales, Raymond L. J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Review Article Botulinum toxin (BT) is used to treat a large number of muscle hyperactivity syndromes. Its use in dystonia, however, is still one of the most important indications for BT therapy. When BT is injected into dystonic muscles, it produces a peripheral paresis which is localised, well controllable and follows a distinct and predictable time course of around 3 months. Adverse effects are always transient and usually mild, long-term application is safe. With this profile BT can be used to treat cranial dystonia, cervical dystonia and limb dystonia including writer’s and musician's cramps. The recent introduction of BT high dose therapy also allows to treat more wide-spread dystonia including segmental and generalised dystonia. BT can easily be combined with other anti-dystonic treatments such as deep brain stimulation and intrathecal baclofen application. Best treatment results are obtained when BT therapy is integrated in the multimodal and long-term 'multilayer concept of treatment of dystonia'. The biggest challenge for the future will be to deliver state of the art BT therapy to all dystonia patients in need, regardless of whether they live in developed countries or beyond. Springer Vienna 2020-10-30 2021 /pmc/articles/PMC8099791/ /pubmed/33125571 http://dx.doi.org/10.1007/s00702-020-02266-z Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Neurology and Preclinical Neurological Studies - Review Article Dressler, Dirk Adib Saberi, Fereshte Rosales, Raymond L. Botulinum toxin therapy of dystonia |
title | Botulinum toxin therapy of dystonia |
title_full | Botulinum toxin therapy of dystonia |
title_fullStr | Botulinum toxin therapy of dystonia |
title_full_unstemmed | Botulinum toxin therapy of dystonia |
title_short | Botulinum toxin therapy of dystonia |
title_sort | botulinum toxin therapy of dystonia |
topic | Neurology and Preclinical Neurological Studies - Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099791/ https://www.ncbi.nlm.nih.gov/pubmed/33125571 http://dx.doi.org/10.1007/s00702-020-02266-z |
work_keys_str_mv | AT dresslerdirk botulinumtoxintherapyofdystonia AT adibsaberifereshte botulinumtoxintherapyofdystonia AT rosalesraymondl botulinumtoxintherapyofdystonia |